Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck buys cancer firm Rigontec
by Lisa M. Jarvis
September 11, 2017
| A version of this story appeared in
Volume 95, Issue 36
Bolstering its immuno-oncology pipeline, Merck & Co. will pay roughly $135 million to acquire the German biotech firm Rigontec. The deal adds RNA-based therapies targeting the retinoic acid-inducible gene I (RIG-I) pathway, a component of the innate immune system, and includes a RIG-I agonist in Phase I studies as a cancer treatment. Investors in Rigontec, which was spun off of the University of Bonn in 2014, could receive another $415 million if certain milestones are reached.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter